Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® in Adults with Non-Transfusion Dependent Beta Thalassemia Biotech Investing
New Data Shows AbbVie's VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment Biotech Investing
U.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C Biotech Investing
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma Biotech Investing
Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations Pharmaceutical Investing
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results Medical Device Investing
Johnson & Johnson Releases 2020 Health for Humanity Report Highlighting Performance and Progress on Environmental, Social and Governance Priorities Medical Device Investing
Merck Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19 Pharmaceutical Investing
U.S. FDA Approves PREVNAR 20, Pfizer's Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older Pharmaceutical Investing
